bioRxiv preprint doi: https://doi.org/10.1101/2020.10.14.335893; this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1	<b>Co-infection of influenza A virus enhances SARS-CoV-2 infectivity</b>		
2	Lei Bai <sup>1,†</sup> , Yongliang Zhao <sup>1,†</sup> , Jiazhen Dong <sup>1,†</sup> , Simeng Liang <sup>1,†</sup> , Ming Guo <sup>1,†</sup> , Xinjin Liu <sup>1</sup> ,		
3	Xin Wang <sup>1</sup> , Zhixiang Huang <sup>1</sup> , Xiaoyi Sun <sup>1</sup> , Zhen Zhang <sup>1</sup> , Lianghui Dong <sup>1</sup> , Qianyun Liu <sup>1</sup> ,		
4	Yucheng Zheng <sup>1</sup> , Danping Niu <sup>1</sup> , Min Xiang <sup>1</sup> , Kun Song <sup>1</sup> , Jiajie Ye <sup>1</sup> , Wenchao Zheng <sup>1</sup> ,		
5	Zhidong Tang <sup>1</sup> , Mingliang Tang <sup>1</sup> , Yu Zhou <sup>1</sup> , Chao Shen <sup>1</sup> , Ming Dai <sup>3</sup> , Li Zhou <sup>1</sup> , Yu Chen <sup>1</sup>		
6	Huan Yan <sup>1</sup> , Ke Lan <sup>1,2,3,*</sup> and Ke Xu <sup>1,*</sup>		
7			
8	<sup>1</sup> State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan		
9	430072, P.R. China		
10	<sup>2</sup> Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan		
11	430072, P.R. China		
12	<sup>3</sup> Animal Biosafety Level 3 Laboratory, Wuhan University, Wuhan 430072, P.R. China		
13			
14	*Corresponding authors. Address correspondence and reprint requests to Dr. Ke Xu (E-		
15	mail: xuke03@whu.edu.cn, Tel: 86-27-68756997, Fax: 86-27-68754592) and Dr. Ke Lan		
16	(E-mail: klan@whu.edu.cn, Tel: 86-27- 68788897, Fax: 86-27-68754592)		
17			

18 <sup>†</sup>These authors contributed equally to this work.

## 19 Abstract

20	The upcoming flu season in the northern hemisphere merging with the current COVID-19	
21	pandemic raises a potentially severe threat to public health. Through experimental co-	
22	infection of IAV with either pseudotyped or SARS-CoV-2 live virus, we found that IAV	
23	pre-infection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell	
24	types. Remarkably, increased SARS-CoV-2 viral load and more severe lung damage were	
25	observed in mice co-infected with IAV in vivo. Moreover, such enhancement of SARS-	
26	CoV-2 infectivity was not seen with several other viruses probably due to a unique IAV	
27	segment as an inducer to elevate ACE2 expression. This study illustrates that IAV has a	
28	special nature to aggravate SARS-CoV-2 infection, and prevention of IAV is of great	
29	significance during the COVID-19 pandemic.	

#### 30 Introduction

The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at 31 the end of 2019 has become pandemic worldwide. Up to date, there had been more than 36 32 million confirmed infected cases and 1 million deaths globally (https://covid19.who.int/). 33 The ending time and the final severity of the current COVID-19 pandemic wave are still 34 35 uncertain. Meanwhile, the upcoming seasonal influenza merging with the current pandemic might bring more challenges and pose a bigger threat to public health. There are many 36 debates on whether seasonal flu would impact the severity of the COVID-19 pandemic and 37 whether massive influenza vaccination is necessary for the coming winter. However, no 38 experimental evidence is available concerning IAV and SARS-CoV-2 co-infection. 39 It is well known that disease symptoms from SARS-CoV-2 and IAV infections are quite 40 41 similar, such as fever, cough, pneumonia, acute respiratory distress syndrome, etc(1, 2). Moreover, both SARS-CoV-2 and IAV are airborne transmitted pathogens that infect the 42 same human tissues such as the respiratory tract, nasal, bronchial, and alveolar epithelial 43 cultures(3, 4). Besides, alveolar type II cells (AT2 pneumocytes) appeared to be 44 preferentially infected by SARS-CoV-2, which were also the primary site of IAV 45 replication(5, 6). Therefore, the overlap of the COVID-19 pandemic and seasonal influenza 46 47 would pose a large population under the high risks of co-occurrent infection by these two viruses(7). 48

Unfortunately, during the last winter flu season in the southern hemisphere, there was
little epidemiological evidence about the interaction between COVID-19 and flu, probably

51	due to a low IAV infection rate resulted from social distancing $(8, 9)$ . A case report showed			
52	that three out of four SARS-CoV-2 and IAV co-infected patients rapidly develop to			
53	respiratory deterioration $(10)$ . On the contrary, other reports only observed mild symptoms			
54	in limited co-infection outpatients(11). Thus, the clinical co-infection outcomes are still			
55	unclear when a large population will face the threats of both viruses.			
56	In this study, we tested whether IAV infection could affect the subsequent SARS-CoV-2			
57	infection in both infected cells and mice. The results demonstrate that the pre-infection of			
58	IAV strongly enhances the infectivity of SARS-CoV-2 by boosting viral entry in the cells			
59	and by elevating viral load plus more severe lung damage in infected mice. These data			
60	suggest a clear auxo-action of IAV on SARS-CoV-2 infection, which implies the great			
61	importance of influenza virus and SARS-CoV-2 co-infection to public health.			

#### 62 **Results**

#### 63 IAV promotes SARS-CoV-2 virus infectivity.

To study the interaction between IAV and SARS-CoV-2, A549 (a hypotriploid alveolar 64 basal epithelial cell line) cells that are susceptible to IAV infection but usually do not 65 support SARS-CoV-2 infection were applied to test whether IAV pre-infection would 66 67 modulate the infectivity of SARS-CoV-2. Pseudotyped VSV luciferase-reporter particles bearing SARS-CoV-2 spike protein (pSARS-CoV-2) were used to reflect the virus entry 68 activity(12). The cells were firstly infected with IAV (A/WSN/1933[H1N1]) or mock-69 70 infected for 6 h, 12 h, or 24 h respectively, and then infected with the pSARS-CoV-2 virus for another 24 h (experimental scheme shown in Fig.1A). The data in Fig. 1B showed that 71 A549 was converted to be highly sensitive (up to 10,000-fold) against the pSARS-CoV-2 72 73 virus after different doses of IAV infections (from low MOI of 0.01 to high MOI of 1, also shown by pSARS-CoV-2 with mCherry reporter in Fig. S1). In contrast, the pre-infection 74 of IAV had no impacts on pseudotyped VSV particles bearing VSV-G protein (Fig.1C). We 75 76 further tested more cell lines to show that the enhancement of the pSARS-CoV-2 infectivity by IAV was a general effect although the increased folds were different (lower basal level 77 of infectivity, higher enhancement fold) (Fig.1D). 78

To validate the above results, we substituted the pSARS-CoV-2 with the SARS-CoV-2 live (experimental scheme shown in Fig.1E). We found that the pre-infection of IAV strongly increased the copy numbers of the SARS-CoV-2 genome (E and N genes) in both cell lysates and supernatants of A549 (~15 folds) (Fig.1F). Notably, in Calu-3 (Fig.1G) and 83 NHBE (Fig.1H) cells that are initially susceptible to SARS-CoV-2, IAV pre-infection could

- 84 further increase >5 folds of SARS-CoV-2 infectivity.
- Collectively, these data suggest an auxo-action of IAV on SARS-CoV-2 in a broad range of cell types.
- 87 IAV and SARS-CoV-2 co-infection in mice results in increased SARS-CoV-2 viral
- 88 load and more severe lung damage.

The hACE2 transgenic mice were applied to study the interaction between IAV and 89 SARS-CoV-2 in vivo. Mice were infected with 3x10<sup>5</sup> PFU of SARS-CoV-2 with or without 90 91 2000 PFU of IAV pre-infection and were then sacrificed two days later after SARS-CoV-2 infection (the experimental scheme is shown in Fig. 2A). The viral RNA genome copies 92 from lung homogenates confirmed that SARS-CoV-2 efficiently infected both groups 93 (more than  $4 \times 10^8$  N gene copies) (Fig. 2B), while the influenza NP gene was only detected 94 in IAV pre-infection group (Fig. 2B). Intriguingly, a significant increase in SARS-CoV-2 95 viral load (12.9-fold increase in E gene and 6.6-fold increase in N gene) was observed in 96 97 lung homogenates from co-infection mice compared to that from SARS-CoV-2 singleinfected mice (Fig. 2C). The histological data in Fig. 2D further illustrated that IAV and 98 SARS-CoV-2 co-infection induced more severe lung pathologic changes with massive 99 100 infiltrating cells and obvious alveolar necrosis as compared to SARS-CoV-2 single infection or mock infection. 101

## 102 IAV components specifically facilitate the entry process of SARS-CoV-2.

103 We further tested if several other viruses on hand had similar effects to promote SARS-

104 CoV-2 infection. To our surprise, neither Sendai virus (SeV) (Fig. 3A), human rhinovirus 105 (HRV3) (Fig. 3B), human parainfluenza virus (HPIV) (Fig. 3C), human respiratory 106 syncytial virus (HRSV) (Fig. 3C) nor human enterovirus 71 (EV71) (Fig. 3C) could 107 stimulate SARS-CoV-2 infection.

- 108 To explore how IAV promotes SARS-CoV-2 infection, we transfected A549 cells with
- 109 eight individual viral genome segments of IAV to test if any of them could promote SARS-

110 CoV-2 infectivity. The data in Fig. 3D and Fig. 3E showed that IAV segment-2 expression

111 strongly stimulated SARS-CoV-2 multiplication in both SARS-CoV-2-infected cell lysates

and supernatant.

## 113 IAV infection induces elevated ACE2 expression.

As IAV strongly increased the pseudotyped SARS-CoV-2 infection, we examined the 114 115 viral entry process. It was reported that the cellular receptor angiotensin-converting enzyme 2 (ACE2)(13, 14), together with transmembrane serine protease 2 (TMPRSS2) 116 (15), Furin(16) and cathepsin L (CatL)(17, 18), mediated SARS-CoV-2 viral entry. In IAV-117 infected cells, we found that the mRNA level of ACE2 and TMPRSS2, but not Furin and 118 CatL were increased around three folds (A549 in Fig. 4A, Calu-3 in Fig. S2). An obvious 119 switch of intracellular ACE2 expression was triggered at 12 h post-IAV-infection (Fig. 4C). 120 121 In the meantime, influenza NP, Mx1, and ISG54 increased accordingly confirming a successful infection of IAV (Fig. 4B). 122

- 123 Interestingly, ACE2 mRNA level increased more dramatically in IAV and SARS-CoV-2
- 124 co-infection cells with 28 folds in A549 (Fig. 4D), 5 folds in Calu-3 (Fig. 4E), 6 folds in

125	NHBE (Fig. 4F) respectively. The mRNA and protein levels (Fig. 4G) of ACE2 also			
126	increased accordingly in lung homogenates from co-infection mice.			
127	When the cell mixture was transduced by lentivirus coding ACE2-sgRNA to knockdown			
128	ACE2 expression (Fig. 4H), the IAV-mediated enhancement of SARS-CoV-2 infection was			
129	totally abolished (Fig. 4I). Consist of this, ACE2 mRNA levels increased 13.8-fold in			
130	SARS-CoV-2-infected cells expressing segment-2 compared to that in control cells			
131	transfected with vector (Fig. 4J). Again, the enhanced SARS-CoV-2 infectivity mediated			
132	by segment-2 could be blocked in ACE2 knock-down cells (Fig. 4K).			
133	The data indicated that IAV permitted increased SARS-CoV-2 infection through the up-			
134	regulation of ACE2 expression.			
135	Enhanced SARS-CoV-2 infectivity is independent of IFN signaling.			
136	ACE2 was reported to be an interferon-stimulated gene (ISG) in human airway epithelial			
137	cells(19). IAV infection will also stimulate type I IFN signaling. We, therefore, tested			
137 138				
	cells(19). IAV infection will also stimulate type I IFN signaling. We, therefore, tested			
138	cells(19). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were			
138 139	cells(19). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were firstly pre-treated with different doses of IFN $\alpha$ (Fig. 5) and IFN $\gamma$ (Fig. S3 A-C) and then			
138 139 140	cells(19). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were firstly pre-treated with different doses of IFN $\alpha$ (Fig. 5) and IFN $\gamma$ (Fig. S3 A-C) and then infected with pSARS-CoV-2. The data showed that IFN $\alpha$ could not promote the pSARS-			
138 139 140 141	cells( <i>19</i> ). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were firstly pre-treated with different doses of IFN $\alpha$ (Fig. 5) and IFN $\gamma$ (Fig. S3 A-C) and then infected with pSARS-CoV-2. The data showed that IFN $\alpha$ could not promote the pSARS-CoV-2 infectivity in A549 cells (Fig. 5A), but rather significantly inhibit pSARS-CoV-2			
138 139 140 141 142	cells( <i>19</i> ). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were firstly pre-treated with different doses of IFN $\alpha$ (Fig. 5) and IFN $\gamma$ (Fig. S3 A-C) and then infected with pSARS-CoV-2. The data showed that IFN $\alpha$ could not promote the pSARS-CoV-2 infectivity in A549 cells (Fig. 5A), but rather significantly inhibit pSARS-CoV-2 infectivity in Calu-3 (Fig. 5D) and Huh-7 (Fig. 5G) cells. Compared with the mRNA levels			
138 139 140 141 142 143	cells( <i>19</i> ). IAV infection will also stimulate type I IFN signaling. We, therefore, tested whether the augment of ACE2 expression is dependent on IFN or not. For this, cells were firstly pre-treated with different doses of IFN $\alpha$ (Fig. 5) and IFN $\gamma$ (Fig. S3 A-C) and then infected with pSARS-CoV-2. The data showed that IFN $\alpha$ could not promote the pSARS-CoV-2 infectivity in A549 cells (Fig. 5A), but rather significantly inhibit pSARS-CoV-2 infectivity in Calu-3 (Fig. 5D) and Huh-7 (Fig. 5G) cells. Compared with the mRNA levels of ISG54 (Fig. 5 B, E, H), the mRNA levels of ACE2 and TMPRSS2 were only mildly			

- 146 mediated viral entry was not affected by IFN.
- 147 Moreover, in IFNAR<sup>-/-</sup> A549 cells, the enhanced infectivity of pSARS-CoV-2 under IAV
- 148 co-infection remained (Fig. 5J). By contrast to the decreased levels of ISG54 in IFNAR<sup>-/-</sup>
- 149 A549 cells (Fig. S3D and Fig. 5K), the mRNA levels of ACE2 and TMPRSS2 still
- 150 increased in IFNAR<sup>-/-</sup> A549 cells under IAV infection (Fig. 5L). The results strongly
- 151 suggested that SARS-CoV-2 responded to IAV infection rather than IFN signaling for a
- 152 favorable viral infection.

#### 153 **Discussion**

Recently, there are many discussions about the possible impacts of the upcoming flu 154 season on the current COVID-19 pandemic. Speculations have been raised that infection 155 of IAV could induce more severe disease for the secondary SARS-CoV-2 infection, or co-156 infection of these two viruses cause more serious illness. However, no experimental data 157 are available to show the relationship between IAV and SARS-CoV-2 yet. In this study, we 158 provide the first experimental evidence that the pre-infection of IAV strongly promotes 159 SARS-CoV-2 virus entry and infectivity in co-infected cells and animals. It emphasizes 160 that influenza prevention during the SARS-CoV-2 pandemic season is of great importance. 161 Co-infection of viruses frequently occurs in nature. Some studies showed positive 162 interaction between the dengue virus and the Zika virus via antibody-dependent 163 164 enhancement(20). Other studies showed negative interactions between the common cold virus and SARS-CoV-2 via pre-existing immunity(21). By co-infection with IAV and 165 pseudotyped or live SARS-CoV-2, we observed a great enhancement of SARS-CoV-2 166 infectivity both in cell culture and in vivo in infected mice. Such enhancement was 167 associated with the increased expression level of ACE2 which is a major receptor for 168 SARS-CoV-2 to enter a host cell. We detected a 2-3 folds increase in ACE2 mRNA level 169 170 post-IAV-infection (A549 cells). However, a much higher increase (28 folds) in the ACE2 mRNA level could be detected under IAV and SARS-CoV-2 co-infection. We suspected 171 that IAV infection induced a mild expression of ACE2 to permit SARS-CoV-2 virus entry 172 so that the subsequent multiplication of SARS-CoV-2 would further enhance ACE2 173

174 expression in a positive feedback pattern(19).

Intriguingly, among all the viruses tested on hand, only IAV but not SeV, HRV3, HPIV, 175 HRSV, or EV71 promoted SARS-CoV-2 infection. The three viruses of HRV3, HPIV, and 176 HRSV are all prevalent pathogens to cause common cold in humans but had no effects on 177 SARS-CoV-2 infectivity. EV71 is a major causative agent for hand-foot-and-mouth disease 178 179 in young children, but again had little influence on SARS-CoV-2 infection. Furthermore, we confirmed the effects of IAV by H1N1 and H3N2 natural isolates (Fig. S4A), and the 180 infectivity of the current D614G mutant SARS-CoV-2 can also be stimulated by IAV pre-181 182 infection (Fig. S4B). The unique feature for IAV to augment SARS-CoV-2 infectivity indicates that the influenza virus is the key pathogen of prevention and control during the 183 current coronavirus pandemic. 184 185 Among the eight segments of IAV, segment-2 encoding PB1 promotes ACE2 expression

and SARS-CoV-2 infectivity at the highest level. The detailed molecular mechanism 186 underlying PB1 mediated SARS-CoV-2 enhancement needs further study. Nevertheless, 187 the IAV PB1 segment encodes multiple viral proteins including PB1, PB1-F2, PB1-N40 to 188 modulate host cells(22). PB1-F2 is a pro-apoptotic factor and can regulate innate 189 immunity(23). PB1-N40 interacts with many host factors and contributes to viral 190 191 pathogenicity(24). After all, the fact that the IAV PB1 segment could promote SARS-CoV-2 infection further confirms a unique positive interaction between IAV and SARS-CoV-2. 192 Importantly, the enhancement phenotype in IAV and SARS-CoV-2 co-infection is 193 independent of IFN signaling. Therefore, influenza vaccination should be recommended to 194

- 195 people under the high risk of co-infection. Our findings remind the society that surveillance
- 196 of co-infection is encouraged in the coming winter. And for sure, social distance and mask-
- 197 wearing are beneficial to protect people from attacks of either or both the influenza virus.

#### 198 Methods

#### 199 Cells and viruses.

200 The 293T, A549, Huh-7, MDCK, and Vero E6, WI-38, WI-38 VA-13, and BEAS-2B were

- 201 obtained from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM;
- Gibco) supplemented with 10% foetal bovine serum (FBS), Calu-3 (ATCC) was maintained in DMEM supplemented with 20% FBS. NCI-H292(ATCC) was maintained
- with RPMI-1640 (Gibco) supplemented with 20% FBS. Normal Human Bronchial
- Epithelial cells (NHBE) cells (ATCC) were maintained in airway epithelial cell basal medium (ATCC PCS300030) supplemented with Bronchial/Tracheal Epithelial Cell Growth Kit (ATCC PCS-300-040). All cells were incubated at 37 °C, 5% CO2.

209 The A/WSN/33 virus was generated by reverse genetics as previously described(25). H1N1(A/Sichuan/01/2009) and H3N2 (A/Donghu/312/2006) were kindly provided by the 210 Influenza Center in China CDC. Human rhinovirus (HRV3), human respiratory syncytial 211 212 virus (HRSV), or human enterovirus 71 (EV71) were purchased from ATCC and stocked accordingly. The human parainfluenza virus (HPIV) was obtained from Prof. MingZhou 213 Chen, Wuhan University. Sendai virus (SeV) was provided by Prof. Tianxian Li, Wuhan 214 215 Institute of Virology. The SARS-CoV-2 live virus (strain IVCAS 6.7512) was provided by the National Virus Resource, Wuhan Institute of Virology, Chinese Academy of Sciences. 216 Plasmids and transfection. 217

218 The SARS-CoV-2-S-Δ18 expressing plasmid was a gift from Prof. Ningshao Xia, Xiamen

University. The eight WSN viral segments in pHW2000 plasmid were kindly provided by
Prof. Hans Klenk, Marburg University. The DNA transfection reagent Fugene HD was
purchased from Promega and the transfection was performed according to manuscript
procedures.

#### 223 **Pseudotype virus production.**

224 The pseudotyped VSV- $\Delta G$  viruses expressing either luciferase reporter or mCherry 225 reporter were provided by Prof. Ningshao Xia, Xiamen University. To produce

 $226 pseudotyped VSV-\Delta G-Luc/mCherry bearing SARS-CoV-2 spike protein (pSARS-CoV-2),$ 

227 Vero E6 cells were seeded in 10 cm dish and transfected simultaneously with 15 μg SARS-

228 CoV-2-S-\Delta18 plasmid by Lipofectamine 3000 (Thermo). Forty-eight hours post-

transfection, 150  $\mu$ l pseudotyped VSV- $\Delta$ G bearing VSV-G protein were used to infect Vero

E6 cells. Cell supernatants were collected after another 24 hours clearing from cell debris

by centrifugation at 3000rpm for 6 minutes, aliquoted and stored at -80 °C.

#### 232 Luciferase-based cell entry assay

Target cells were seeded in 48-well plates and inoculated, in triplicate, with equivalent

volumes of pseudotyped virus stocks with 1:5 dilution in DMEM (3% FBS) with or without

- 235 IAV pre-infection. At 24 h post-pseudotype-infection, the luciferase activities were
- 236 measured with the Luciferase Assay System (Promega E4550).

## 237 Virus infection and IFN treatment

238 For IAV infection, cells were washed with PBS and then incubated with viruses at different

MOIs (from 0.01 to 1) in infection medium (DMEM, supplemented with 2% FBS, 1%

240 penicillin/streptomycin) at 37 °C, 5% CO2.

- of 0.01 in infection medium (DMEM, 1% penicillin/streptomycin) and incubated at 37 °C,
- 243 5% CO2 for 1 hour with or without 12 h IAV pre-infection (MOI 0.1). Cells were then
- 244 washed with PBS two times and then incubated in culture medium (DMEM, supplemented
- with 5% FBS, 1% penicillin/streptomycin) at 37 °C, 5% CO2 for 48 hours.
- For SeV, HRV3, HPIV, HRSV, or EV71 infection, cells were washed with PBS and then
- 247 incubated with indicated viruses in infection medium (DMEM, supplemented with 3% FBS,
- <sup>248</sup> 1% penicillin/streptomycin) and incubated at 37 °C, 5% CO2 for 12 hours.
- 249 For IFN treatment, recombinant human IFNα 2a (Beyotime, P5646) and IFNγ (Beyotime,
- 250 P5664) were dissolved in 0.1% BSA and diluted in DMEM with 10% FBS, and then
- admitted to cells for 12 hours at indicated doses.

#### 252 Real-time reverse-transcriptase-polymerase chain reaction

- 253 The mRNA levels of indicated genes were quantified by quantitative PCR with reverse
- transcription (qRT–PCR). Purified RNAs extracted by TRIzol (Invitrogen<sup>TM</sup>,15596018)
- were subjected to reverse transcription with oligo dT primer (using Takara cat#RR037A
- Kit), and then the corresponding cDNAs were quantified using Hieff qPCR SYBR Green
- 257 Master Mix (Yeason). Thermal cycling was performed in a 384-well reaction plate
- 258 (ThermoFisher, 4343814). Gene-specific primers were shown in Supplementary Table 1.
- 259 All the mRNA levels were normalized by  $\beta$ -actin in the same cell.
- 260 The relative number of SARS-CoV-2 viral genome copy number were determined using

Taqman RT-PCR Kit (Yeason). To acutely quantify the absolute number of SARS-CoV-2
genome, a standard curve by measuring the SARS-CoV-2 N gene constructed in the pCMVN plasmid was applied. All the SARS-CoV-2 genome copy numbers were normalized by
GADPH in the same cell.

### 265 Western blot analysis.

266 For western blots, cells were lysed in RIPA buffer on ice for 30 minutes and were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected 267 to western blot analysis. For mice experiments, half lung tissue from each mouse was 268 269 homogenized in PBS followed by boiling in SDS lysis buffer (GE) at 100°C, 30 minutes. Rabbit monoclonal antibody against ACE2 (Abclonal, A4612, 1:1000), mouse monoclonal 270 antibody against SARS-CoV Nucleoprotein (Sino Biological, 40143-MM05, 1:1000), anti-271 272 actin (Abclonal, 1:1000), were purchased commercially. The anti-influenza virus-NP was kindly provided by Prof. Ningshao. Xia. Peroxidase-conjugated secondary antibodies 273 (Antgene, 1: 5000) were applied accordingly followed by image development with 274 Chemiluminescent HRP Substrate Kit (Millipore Corporation). 275

### 276 Immunofluorescence

A549 cells were fixed and incubated with primary antibodies. The primary antibodies used
in this study were rabbit polyclonal antibody against ACE2 for immunofluorescence (Sino
Biological, 10108-T26) and anti-influenza virus-NP (kindly provided by Prof. Ningshao
Xia). The Alexa Fluor dye-conjugated secondary antibodies (Alexa Fluor R488, Invitrogen;
Alexa Fluor M555, Invitrogen) and DAPI (Beyotime, C1002), were admitted afterward

according to standard protocols. Cell imaging was performed on a Leica TCS SP8 confocal
laser scanning microscope (Leica).

#### 284 ACE2 knocking-down cells

Two sgRNAs targeting the hACE2 gene were designed under the protocol in 285 http://chopchop.cbu.uib.no and commercially synthesized to clone in lenti-Cas9-blast 286 287 vector (kindly provided by Prof. Hongbing Shu). The control sgRNA lentivirus construct was also provided by Prof. Hongbing Shu. In brief, A549 cells were plated at 6-well plates 288 and transduced with lentivirus encoding CRISPR-Cas9 system including either ACE2 289 290 sgRNA or control sgRNA. The cell mixtures were selected by blasticidin for one week to obtain ACE2 knocking-down cells. The gene knocking-down efficiencies were confirmed 291 by measuring the ACE2 mRNA level through qRT-PCR analysis. 292

293 Mice

294 The K18 hACE2 transgenic mice purchased from Gempharmatech were housed in ABSL-

295 3 pathogen-free facilities under 12-h light-dark cycles with access to food and water. Mice

were male, age-matched, and grouped for SARS-CoV-2 infection or IAV and SARS-CoV-

297 2 co-infection. At day 0, mice were intranasally infected with PBS or 2000 PFU of WSN

- respectively, and then both groups were intranasally infected with  $3 \times 10^5$  PFU of SARS-
- 299 CoV-2 at Day 2. Another two days later, mice were sacrificed to determine viral loads and
- 300 submitted to histological assay.

301 Histology

302 Lung tissue from infected mice was dissected at Day 2 post-SARS-CoV-2-infection, fixed,

303	and stained using a standard H&E procedure. The slides were scanned and analyzed by the	
304	Wuhan Sci-Meds company. The representative images from three mice in each group were	
305	shown.	
306	Statistical analysis	
307	If not indicated otherwise, Student's t-test was used for two-group comparisons. The *p-	
308	value < 0.05, **p-value < 0.01, ***p-value < 0.001 and ****p-value < 0.0001 were	
309	considered significant. Unless otherwise noted, error bars indicated as mean values with	
310	standard deviation of at least three biological experiments.	

### 311 References and Notes

312	1.	C. Huang et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.		
313		<i>The Lancet</i> <b>395</b> , 497-506 (2020).		
314	2.	C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of global health		
315		concern. The Lancet <b>395</b> , 470-473 (2020).		
316	3.	D. van Riel et al., Human and avian influenza viruses target different cells in the lower respiratory		
317		tract of humans and other mammals. 171, 1215-1223 (2007).		
318	4.	A. St John, A. J. J. o. i. Rathore, Early Insights into Immune Responses during COVID-19. 205,		
319		555-564 (2020).		
320	5.	Z. P. Traylor, F. Aeffner, I. C. J. I. Davis, O. R. Viruses, Influenza A H1N1 induces declines in		
321		alveolar gas exchange in mice consistent with rapid post-infection progression from acute lung		
322		injury to ARDS. 7, (2013).		
323	6.	Y. Hou et al., SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the		
324		Respiratory Tract. Cell 182, (2020).		
325	7.	E. Belongia, M. J. S. Osterholm, COVID-19 and flu, a perfect storm. 368, 1163 (2020).		
326	8.	Y. Liu et al., Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. 582, 557-560 (2020).		
327	9.	S. Olsen et al., Decreased Influenza Activity During the COVID-19 Pandemic - United States,		
328		Australia, Chile, and South Africa, 2020. 69, 1305-1309 (2020).		
329	10.	E. Cuadrado-Payán et al., SARS-CoV-2 and influenza virus co-infection. The Lancet 395, e84		
330		(2020).		
331	11.	X. Zheng et al., Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19		

- 332 Epidemic in Wuhan, China. *Journal of Infection* **81**, e128-e129 (2020).
- 333 12. H. Kleine-Weber et al., Mutations in the Spike Protein of Middle East Respiratory Syndrome
- 334 Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
- 335 *Journal of virology* **93**, e01381-01318 (2019).
- 13. Q. Wang *et al.*, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. 181,
- 337 894-904.e899 (2020).
- 338 14. J. Lan *et al.*, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
- 339 receptor. **581**, 215-220 (2020).
- 340 15. M. Hoffmann et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by
- a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278 (2020).
- 342 16. C. Wu *et al.*, Furin, a potential therapeutic target for COVID-19. *iScience*, 101642 (2020).
- 343 17. C. Grimm, R. Tang, Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?
- 344 *Cell Calcium* **88**, 102212 (2020).
- 345 18. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
- 346 *Cell* **181**, 281-292.e286 (2020).
- 19. C. G. K. Ziegler, S. J. Allon, S. K. Nyquist, I. M. Mbano, J. J. C. Ordovas-Montanes, SARS-CoV-2
- Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected
   in Specific Cell Subsets across Tissues. (2020).
- 20. L. Priyamvada, K. M. Quicke, W. H. Hudson, N. Onlamoon, J. J. P. N. A. U. S. A. Wrammert,
- 351 Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. **113**,
- 352 7852-7857 (2016).

353	21.	J. Mateus et al., Selective an	d cross-reactive SARS-C	CoV-2 T cell	epitopes in	unexposed humans.
-----	-----	--------------------------------	-------------------------	--------------	-------------	-------------------

- 354 *Science*, (2020).
- 355 22. H. M. Wise *et al.*, A complicated message: Identification of a novel PB1-related protein translated
- from influenza A virus segment 2 mRNA. Journal of virology 83, 8021-8031 (2009).
- 23. R. Wang et al., Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy.
- 358 1-16 (2020).
- 359 24. H. Wise *et al.*, Overlapping signals for translational regulation and packaging of influenza A virus
- 360 segment 2. **39**, 7775-7790 (2011).
- 361 25. Q. Han et al., Sumoylation of influenza A virus nucleoprotein is essential for intracellular trafficking
- and virus growth. **88**, 9379-9390 (2014).

## 363 Acknowledgment

364	Funding: This work was supported in part by the National Key Research and Development			
365	Program (grants 2018FYA0900801 to K.X., 2016YFA0502103 to K.L.), the National			
366	Natural Science Foundation of China (grants 31922004 and 81772202 to K.X.),			
367	Application & Frontier Research Program of the Wuhan Government (2019020701011463			
368	to K.X.), and Hubei Innovation Team Foundation (2020CFA015 to K.X. and K.L.).			
369	Author contributions: K.X. and K.L. conceived the project and designed the experiments.			
370	L.B., J. D., M.G., X.W., Z. H., Z. Z., and YC. Z. coordinated the live SARS-CoV-2 study			
371	and performed animal infection experiments. YL. Z. and S. L. conducted pseudotyped virus			
372	infection experiments, IFN treatment experiments, and data analysis. L.B., J. D. solved the			
373	Immunofluorescence, Histopathologic and Immunohistochemical studies. X. L. performed			
374	SeV, HRV3, HPIV, HRSV, EV71 infection experiments. YL. Z and X. L. generated the			
375	mutant virus and performed the related test. L.B., S. L, J. D., and X. L. repeated the key			
376	experiments in infected cells. X. S., Q.L., D. N., M.X., K.S., J.Y., W.Z., Z. T., M. T., Y. Z.,			
377	C.S., M. D., L.Z., Y.C., and H.Y provided technical supports and the materials. L. D. carried			
378	out ACE2 knock-out cells and related analysis. K.X., K.L., S. L, and YL. Z wrote the			
379	manuscript with inputs from all the remaining authors. We also thank our group members			
380	of the SARS-CoV-2 working group in the State Key Laboratory of Virology, Wuhan			
381	University, who work tightly together during this new virus pandemic for their research			
382	spirits and courage. We are grateful to Taikang Insurance Group Co., Ltd, Beijing Taikang			

- 383 Yicai Foundation, and Special Fund for COVID-19 Research of Wuhan University for their
- 384 great supports of this work.

# 385 **Competing interests:**

386 The authors declared there were no competing interests.

## 387 Figure legends

Fig. 1. IAV promotes SARS-CoV-2 virus infectivity. (A) Diagram of the experimental 388 procedure. (B) A549 cells were infected with A/WSN/33 at indicated MOIs. At 6, 12, 24 389 hours post-IAV-infection, cells were infected with pSARS-CoV-2 for another 24 hours. 390 Luciferase activity was measured to reflect virus entry efficiency. P values are from 391 392 unpaired One-way ANOVA. (C) A549 cells were infected with A/WSN/33 at MOI 0.1. At 12 hours post-IAV-infection, cells were infected with VSV-G-Luc for another 24 hours. 393 Luciferase activity was measured to reflect virus entry efficiency. (D) The indicated cells 394 395 were infected with WSN at MOI 0.1. At 12 hours post-IAV-infection, cells were infected with pSARS-CoV-2 for another 24 hours. Luciferase activity was measured to reflect virus 396 entry efficiency. (E) The experimental procedure of IAV and live SARS-CoV-2 co-397 398 infection. A549 (F), Calu-3 (G), and NHBE (H) cells were pre-infected with WSN at MOI 0.1 for 12 hours. Cells were then infected with live SARS-CoV-2 at MOI 0.01 for another 399 48 hours. Total RNA in cell lysates and the supernatant were collected to detect E and N 400 401 gene by Taqman-qRT-PCR. The data were expressed as fold changes of viral RNA levels in IAV pre-infection cells relative to the non-IAV infection control. Values are mean  $\pm$  s.d. 402 of three independent results. \*P≤0.05, \*\*P≤0.01, \*\*\*P≤0.001, \*\*\*\*P≤0.0001. 403 404 Fig. 2. IAV and SARS-CoV-2 co-infection induce more severe pathology in infected mice. (A) Diagram of the experimental procedure. K18 hACE2 transgene mice were firstly 405

406 intranasally infected with 2000 PFU of WSN or PBS at Day 0. Two days post-IAV-infection,

407 mice were intranasally infected with  $3 \times 10^5$  live SARS-CoV-2 or PBS. At day 4, half lung

408	tissues of all the mice were homogenized to detect RNA or protein levels. (B) The			
409	quantitative viral genome copy numbers of SARS-CoV-2 N ( <b>B</b> , left) or IAV NP ( <b>B</b> , right)			
410	were measured. (C) The relative mRNA levels of SARS-CoV-2 E (C, left), N gene (C,			
411	right), were measured from lung homogenates in indicated groups. The data were			
412	expressed as fold changes relative to the non-IAV infection control. (D) Histopathologic			
413	and immunohistochemical studies were performed with lung slide samples in indicated			
414	groups. (B-D) Values are mean $\pm$ s.d. of three independent results. *P $\leq$ 0.05, **P $\leq$ 0.01,			
415	***P≤0.001, ****P≤0.0001.			
416	Fig. 3. The enhancement of SARS-CoV-2 infection especially responses to IAV. (A-C)			
416 417	<b>Fig. 3. The enhancement of SARS-CoV-2 infection especially responses to IAV. (A-C)</b> A549 cells were pre-infected with SeV, HRV3, HPIV, HRSV, or EV71 at indicated doses			
417	A549 cells were pre-infected with SeV, HRV3, HPIV, HRSV, or EV71 at indicated doses			
417 418	A549 cells were pre-infected with SeV, HRV3, HPIV, HRSV, or EV71 at indicated doses for 12 hours respectively. Cells were then infected with pSARS-CoV-2 for another 24 hours			
417 418 419	A549 cells were pre-infected with SeV, HRV3, HPIV, HRSV, or EV71 at indicated doses for 12 hours respectively. Cells were then infected with pSARS-CoV-2 for another 24 hours followed by measuring luciferase activity. ( <b>D</b> and <b>E</b> ) The eight individual segment of WSN			
417 418 419 420	A549 cells were pre-infected with SeV, HRV3, HPIV, HRSV, or EV71 at indicated doses for 12 hours respectively. Cells were then infected with pSARS-CoV-2 for another 24 hours followed by measuring luciferase activity. ( <b>D</b> and <b>E</b> ) The eight individual segment of WSN were transfected to A549 cells 24 hours ahead of live SARS-CoV-2 infection. Total RNA			

424 \*\*\*P≤0.001, \*\*\*\*P≤0.0001.

423

# Fig. 4. ACE2 is essential for IAV to promote SARS-CoV-2 infection. (A and B) A549

control. Values are mean  $\pm$  s.d. of three independent results. \*P $\leq$ 0.05, \*\*P $\leq$ 0.01,

426 cells were mock-infected or infected with WSN at MOI 0.1. At 12 hours post-infection

427 (h.p.i.), total RNAs were extracted from cells, and mRNA of ACE2, TMPRSS2, Furin,

428 CatL (A), or mRNA of NP, Mx1, ISG54 (B)was evaluated by quantitative real-time PCR

429	(qRT-PCR) using SYBR green method. The data were expressed as fold changes relative
430	to the Mock infections. (C) A549 cells were infected with WSN at MOI 0.1. IAV NP
431	proteins (red) and ACE2 (green) were detected by an immunofluorescence assay using a
432	confocal microscope at 12 hours-post-infection. Scale bars were shown. A549 (D), Calu-3
433	(E), and NHBE (F) cells were pre-infected with WSN at MOI 0.1 for 12 hours. Cells were
434	then infected with live SARS-CoV-2 at MOI 0.01 for another 48 hours. Total RNAs were
435	extracted from cells and mRNA of ACE2 was evaluated by quantitative real-time PCR
436	(qRT-PCR) using SYBR green method. The protein expression levels of ACE2, SARS-
437	CoV-2 N gene, IAV NP, and $\beta$ -actin were measured by western blot. (G) The relative
438	mRNA levels of ACE2 were measured from lung homogenates in indicated groups and the
439	protein expression of IAV NP and ACE2 were detected by western blot accordingly. (D-G
440	and J) The data were expressed as fold changes relative to the non-IAV infection control.
441	(H-K) To establish ACE2 knock-down cells, A549 cell mixture was transduced with
442	lentivirus encoding CRISPR-Cas9 system with two guide RNAs targeting ACE2 (sgRNA1
443	and sgRNA2) or control guide RNA respectively. Cells were infected with live SARS-CoV-
444	2 at MOI 0.01 with or without IAV infection under the same procedure as above. The
445	mRNA levels of ACE2 (qRT-PCR) (H) and SARS-CoV-2 E gene (Taqman-qRT-PCR) (I)
446	expression were detected. (J) The mRNA level of ACE2 was detected by qRT-PCR in live
447	SARS-CoV-2-infected cells transfected with either vector of WSN segment-2 respectively.
448	(K) The mRNA levels of the SARS-CoV-2 E gene from either vector- or segment2-
449	transfected cells were measured by Taqman-qRT-PCR at 48 hours post-live-SARS-CoV-2-

infection in the present of control sgRNA or ACE2 sgRNAs. The data were expressed as fold change relative to non-IAV infection control. Values are mean  $\pm$  s.d. of three independent results. \*P $\leq$ 0.05, \*\*P $\leq$ 0.01, \*\*\*P $\leq$ 0.001, \*\*\*\*P $\leq$ 0.0001.

## 453 Fig. 5. Enhanced SARS-CoV-2 infection is independent of IFN signaling. A549 (A, B,

- 454 C), Calu-3 (D, E, F), and Huh-7 (G, H, I) cells were pre-treated with indicated doses of
- 455 IFNα for 12 hours. Cells were then infected with pSARS-CoV-2 for another 24 hours
- 456 followed by measuring luciferase activity and mRNA expression levels of indicated genes.
- 457 The data of mRNA levels were expressed as fold changes relative to non-treatment cells.
- 458 (J-L) WT A549, and IFNAR<sup>-/-</sup>A549 cells were infected with WSN at MOI 0.1 for 12 hours,
- 459 cells were then infected with pSARS-CoV-2 for another 24 hours followed by measuring
- 460 luciferase activity and mRNA expression levels of indicated genes. P values are from
- 461 unpaired One-way ANOVA. Values are mean  $\pm$  s.d. of three independent results. \*P $\leq$ 0.05,
- 462 \*\*P≤0.01, \*\*\*P≤0.001, \*\*\*\*P≤0.0001.

#### 463 Fig. S1 IAV facilitates the entry process of pSARS-CoV-2 (relate to Fig.1).

464 A549 cells were infected with A/WSN/33 at indicated MOIs. At 12, 24 hours post-IAV-

- 465 infection, cells were infected with pSARS-CoV-2 with mCherry reporter for another 24
- 466 hours. Scale bars, 200 μm.

### 467 Fig. S2 IAV infection induces elevated ACE2 expression (relate to Fig.4).


- 468 Calu-3 cells were mock-infected or infected with WSN at MOI of 0.1. At 12 hours h.p.i.,
- total RNAs were extracted from cells, and mRNA of ACE2, TMPRSS2, Furin, CatL, NP,
- 470 Mx1, and ISG54 were evaluated by qRT-PCR using the SYBR green method. The data


- 471 were expressed as fold changes relative to the Mock infections. Values are mean  $\pm$  s.d. of
- 472 three independent results.  $*P \le 0.05$ ,  $**P \le 0.01$ ,  $***P \le 0.001$ ,  $***P \le 0.0001$ .


# 473 Fig. S3 Enhanced SARS-CoV-2 infection is independent of IFN signaling (relate to


- 474 **Fig.5**).
- 475 A549 (A), Calu-3 (B), and Huh-7 (C) cells were pre-treated with indicated doses of IFNy
- 476 for 12 hours. Cells were then infected with pSARS-CoV-2 for another 24 hours followed
- 477 by measuring luciferase activity. (**D**) WT, and IFNAR<sup>-/-</sup>A549 cells were treated with IFN $\alpha$
- 478 at 1000 IU/mL for 12 hours, and the mRNA expression levels of indicated genes were
- 479 measured. Values are mean  $\pm$  s.d. of three independent results. (A-C) P values are from
- 480 unpaired One-way ANOVA. \*P≤0.05, \*\*P≤0.01, \*\*\*P≤0.001, \*\*\*\*P≤0.0001.
- 481 Fig. S4 IAV facilitates viral entry of WT or mutant SARS-CoV-2.
- 482 (A) MDCK cells were pre-infected with WSN (MOI=0.1), H1N1(MOI=1), or H3N2
- 483 (MOI=1) for 12 hours and were then infected with pSARS-CoV-2 for another 24 hours
- 484 followed by measuring luciferase activity. (B) A549 cells were pre-infected with WSN at
- 485 MOI 0.1 for 12 hours and were then infected with D614G mutant pSARS-CoV-2 for
- another 24 hours followed by measuring luciferase activity. Values are mean  $\pm$  s.d. of three
- 487 independent results.  $*P \le 0.05$ ,  $**P \le 0.01$ ,  $***P \le 0.001$ .

Figure 1. IAV promotes SARS-CoV-2 virus infectivity.














Figure 4. ACE2 is essential for IAV to promote SARS-CoV-2 infection.

## Figure 5. Enhanced SARS-CoV-2 infection is independent of IFN signaling.



# Figure S1. IAV facilitates the entry process of pSARS-CoV-2 (Fig.1).







Figure S2. IAV infection induces elevated ACE2 expression (Fig.4).







Figure S4. IAV facilitates viral entry of WT or mutant SARS-CoV-2.



bioRxiv preprint doi: https://doi.org/10.1101/2020.10.14.335893; this version posted October 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Supplementary Table 1. Primers used in this paper.

Primer	Sequence (5'-3')
ACE2	CAAGAGCAAACGGTTGAACAC
	CCAGAGCCTCTCATTGTAGTCT
TMPRSS2	GCAGTGGTTTCTTTACGCTGT
	CCGCAAATGCCGTCCAATG
cathepsin L	TCGCGTCCTCAAGGCAATC
	CACAGTTGCGACTGCTTTCAT
Furin	GCAAAGCGACGGACTAAACG
	TGCCATCGTCCAGAATGGAGA
ISG54	CTGCAACCATGAGTGAGAA
	CCTTTGAGGTGCTTTAGATAG
ISG56	TACAGCAACCATGAGTACAA
	TCAGGTGTTTCACATAGGC
IAV NP-mRNA	GACTCACATGATGATCTGGCA
	CTTGTTCTCCGTCCATTCTCA
IAV NP-vRNA	AACGGCTGGTCTGACTCACATGAT
	AGTGAGCACATCCTGGGATCCATT
Mx1	GTTTCCGAAGTGGACATCGCA
	GTTTCCGAAGTGGACATCGCA
β-actin	CATGTACGTTGCTATCCAGGC
	CATGTACGTTGCTATCCAGGC
SARS2-E	ACACTAGCCATCCTTACTGCGCTTCG
SARS2-N	GCAAATTGTGCAATTTGCGG
GAPDH	CTGCTTAGCACCCCTGGCCA